Skip to main content

Table 3 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Setting

Author

Study groups (n)

In-Hospital Mortality

Reported P-value

Ref

Tertiary care center

Akhabue et al. (2011)

Cefepime resistant P. aeruginosa (213)

20%

0.007

[61]

Susceptible P. aeruginosa (2316)

13%

Brooklyn Antibiotic Resistance Task Force (2002)

Carbapenem resistant P. aeruginosa (10)

20%

> 0.05 (NS)

[60]

Susceptible P. aeruginosa (10)

10%

Cao et al. (2004)

MDR P. aeruginosad (44)

55%

0.05

[57]

Susceptible P. aeruginosa (68)

16%

Eagye et al. (2009)

Meropenem resistant P. aeruginosa (58)

31%

0.152a

[53]

Meropenem susceptible P. aeruginosa (125)

15%

Meropenem resistant P. aeruginosa (58)

31%

0.01a

Control (57)

9%

Evans et al. (2007)

Resistant P. aeruginosae (47)

15%

0.43

[71]

Susceptible P. aeruginosa (73)

21%

Furtado et al. (2011)

SPM-1-producing imipenem resistant P. aeruginosa (5)

60%

0.59

[68]

Non-SPM-1-producing susceptible P. aeruginosa (24)

75%

Gasink et al. (2006)

Fluoroquinolone resistant P. aeruginosa (320)

24%

0.004

[64]

Fluoroquinolone susceptible P. aeruginosa (527)

16%

Hirakata et al. (2003)

blaIMP-positive P. aeruginosa (69)

30.4%

0.41

[69]

blaIMP-negative P. aeruginosa (247)

25.5%

Lautenbach et al. (2010)

Imipenem resistant P. aeruginosa (253)

17%

0.01

[63]

Imipenem susceptible P. aeruginosa (2289)

13%

Morales et al. (2012)

MDR P. aeruginosaf (134)

25%

< 0.05

[49]

Susceptible P. aeruginosa (149)

13%

Resistant P. aeruginosa (119)

22%

<0.05

Susceptible P. aeruginosa (149)

13%

Peña et al. (2013)

Non-MDR P. aeruginosa (27)

55%

0.33

[56]

MDR P. aeruginosag (56)

50%

Scheetz et al. (2006)

Fluoroquinolone resistant P. aeruginosa (79)

32%

0.731

[65]

Fluoroquinolone susceptible P. aeruginosa (136)

29%

Tam et al. (2010)

MDR P. aeruginosah (25)

56%

0.001

[13]

Susceptible P. aeruginosa (84)

17%

Zavascki et al. (2006)

MBL-carrying P. aeruginosa (86)

51.2%

0.003

[70]

Non-MBL-carrying P. aeruginosa (212)

32.1%

ICU

Lambert et al. (2011)

Ceftazidime resistant P. aeruginosa (362)b

43%

NR

[31]

Susceptible P. aeruginosa (1251)b

37%

Ceftazidime resistant P. aeruginosa (82)c

41%

Susceptible P. aeruginosa (280)c

39%

Furtado et al. (2009)

Imipenem resistant P. aeruginosa (63)

49%

0.02

[62]

Control (182)

34%

Kaminski et al. (2011)

Ureido/carboxypenicillin resistant P. aeruginosa (70)

43%

0.56

[66]

Ureido/carboxypenicillin susceptible P. aeruginosa (153)

44%

Paramythiotou et al. (2004)

MDR P. aeruginosai (34)

47%

0.8

[54]

Control (34)

50%

Trouillet et al. (2002)

Piperacillin resistant P. aeruginosa (34)

59%

> 0.05 (NS)

[67]

Piperacillin susceptible P. aeruginosa (101)

50%

Tumbarello et al. 2013

MDR P. aeruginosaj (42)

60%

0.01

[55]

Susceptible P. aeruginosa (68)

35%

  1. aAdjusted for time at risk; bPatients with pneumonia; cPatients with bloodstream infections; dAbsence of susceptibility to three or more antibiotics: ceftazidime, cefepime, piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem; eAbsence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to carbapenems, β-lactams, quinolones, tobramycin, and gentamicin; gAbsence of susceptibility to one or more agent in three or more anti-pseudomonal antimicrobial categories (carbapenems, β-lactams, quinolones, tobramycin, and gentamicin); hAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones; iAbsence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin; jAbsence of susceptibility to one or more antipseudomonal agent in 3 or more of the following categories: β-lactam/β-lactamase inhibitors, cephalosporins, carbapenems, quinolones and aminoglycosides.